BioStem Technologies (BSEM) Stock Price, News & Analysis

Company Overview

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

Key Stats

• Today's Range: $3.04 to $3.33
• 50-Day Range: $3.00 to $4.14
• 52-Week Range: $2.25 to $8.40
• Volume: 42,756 shs
• Average Volume: 84,028 shs
• Market Capitalization: $56.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Buy

BioStem Technologies Stock Analysis - MarketRank™

BioStem Technologies scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

BioStem Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

BioStem Technologies has a consensus price target of $9.00, representing about 185.7% upside from its current price of $3.15.

Amount of Analyst Coverage

BioStem Technologies has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioStem Technologies are expected to grow in the coming year, from ($1.95) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioStem Technologies is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioStem Technologies is -2.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.20% of the float of BioStem Technologies has been sold short.

Short Interest Ratio / Days to Cover

BioStem Technologies has a short interest ratio ("days to cover") of 4.54.

Change versus previous month

Short interest in BioStem Technologies has recently increased by 0.53%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioStem Technologies does not currently pay a dividend.

Dividend Growth

BioStem Technologies does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: -0.24

News Sentiment

BioStem Technologies has a news sentiment score of -0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for BioStem Technologies this week, compared to 1 article on an average week.

Search Interest

35 people have searched for BSEM on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.

MarketBeat Follows

6 people have added BioStem Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioStem Technologies insiders have not sold or bought any company stock.

Percentage Held by Institutions

BioStem Technologies has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 8/18/2026
• Micro-Cap Virtual Conference: 8/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BSEM
• Previous Symbol: PINK:BSEM
• CIK: 1658678
• Web: www.biostemtechnologies.com
• Phone: 954-380-8342
• Fax: N/A
• Employees: N/A
• Year Founded: 2015

Price Target and Rating

• Average Price Target for BioStem Technologies: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +185.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $292.21 million
• Price / Sales: 0.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 17,849,000
• Free Float: N/A
• Market Cap: $56.22 million
• Optionable: N/A
• Beta: 0.11